Also, pan-HER, composed of a mixture of six monoclonal antibodies targeted against EGFR, HER2,and HER3, demonstrated antiproliferative and radiosensitizing impact in human lung and head and neck cancer (Francis et al., 2016). This evidence concerns the gene ERBB2 and head and neck cancer.